Russia will jointly produce Sputnik V vaccine for COVID-19 with India: Russian envoy Nikolay Kudashev
Russian envoy to India Nikolay Kudashev on December 21 said Moscow will jointly produce the Sputnik V vaccine for COVID-19 along side New Delhi and it’ll be manufactured by Indian pharma major Dr Reddy’s Laboratories. “We are working very hard to fight COVID-19 along side India, and are now advancing to jointly produce Sputnik V vaccine at the capacities of Dr Reddy’s Laboratories to be utilized in India, Russia and other countries,” Kudashev said, addressing a news conference .
“We have supported one another during a big way earlier this year once we managed to repatriate thousands of Russian and Indian nationals to their respective home countries,” he added. On August 11, Russia became the world’s first country to register a coronavirus vaccine, dubbed Sputnik V.
The vaccine was developed by the Gamaleya Research Institute while the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, is investing within the production and promotion of the vaccine abroad. Sputnik V vaccine has shown 92 per cent efficacy in preventing COVID-19, consistent with the interim trial results announced by the country’s health ministry.
In September 2020, Dr Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As a part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr Reddy’s upon regulatory approval in India.
Kudashev said tons of efforts are aimed toward coordination within the international arena, including the planet Health Organization and BRICS, where Russia possesses advanced healthcare mechanisms and initiatives, including Tuberculosis Network, Vaccine research facility , and Early Warning System to stop the spread of infectious diseases.